We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.51B
1-Year Est. Return
164.17%
This Fund
S&P 500
This Quarter
Est. Return
-3.89%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$2.3B
AUM Growth
-$140M
(-5.7%)
Cap. Flow
+$106M
Cap. Flow
% of AUM
4.61%
Top 10 Holdings %
Top 10 Hldgs %
42.59%
Holding
80
New
11
Increased
12
Reduced
36
Closed
4
Top Buys
| 1 |
CTLT
CATALENT, INC.
CTLT
|
+$37.7M |
| 2 |
DexCom
DXCM
|
+$37.6M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$34.7M |
| 4 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
+$33.2M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$31.7M |
Top Sells
| 1 |
ONEM
1Life Healthcare
ONEM
|
+$38.9M |
| 2 |
Xenon Pharmaceuticals
XENE
|
+$38.2M |
| 3 |
Pliant Therapeutics
PLRX
|
+$27.1M |
| 4 |
AKRO
Akero Therapeutics
AKRO
|
+$26.2M |
| 5 |
Replimune Group
REPL
|
+$24.2M |
Sector Composition
| 1 | Healthcare | 98.78% |
| 2 | Industrials | 1.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
| $203M | 8.83% |
18,346,861
-1,902,928
| -9% | -$23.5M |
|
2
Krystal Biotech
KRYS
$10.2B
| $153M | 6.65% |
1,913,280
+16,635
| +0.9% | +$1.31M |
|
|
ISEE
3
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $102M | 4.44% |
4,205,206
-296,905
| -7% | -$6.5M |
|
|
DCPH
4
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $86.2M | 3.74% |
5,582,105
+1,988,788
| +55% | +$33.2M |
|
|
AKRO
5
DELISTED
Akero Therapeutics
AKRO
| $78.2M | 3.39% |
2,044,389
-588,523
| -22% | -$26.2M |
|
|
6
Pliant Therapeutics
PLRX
$68.7M
| $77.8M | 3.38% |
2,925,648
-952,951
| -25% | -$27.1M |
|
7
Fate Therapeutics
FATE
$346M
| $73.9M | 3.2% |
12,957,222
| – | – |
|
8
Kymera Therapeutics
KYMR
$9.31B
| $71.4M | 3.1% |
2,410,769
-263,068
| -10% | -$8.48M |
|
9
Celldex Therapeutics
CLDX
$3.02B
| $67.6M | 2.93% |
1,879,739
-97,712
| -5% | -$4.22M |
|
|
10
Replimune Group
REPL
$825M
| $67.3M | 2.92% |
3,811,988
-1,019,721
| -21% | -$24.2M |
|
11
Zymeworks
ZYME
$1.81B
| $54.9M | 2.38% |
6,067,918
-108,000
| -2% | -$942K |
|
12
Penumbra
PEN
$12.5B
| $52.4M | 2.27% |
187,992
-33,817
| -15% | -$8.63M |
|
13
LivaNova
LIVN
$4.4B
| $51.7M | 2.24% |
1,186,418
+80,009
| +7% | +$4.05M |
|
14
Beam Therapeutics
BEAM
$3.19B
| $49.4M | 2.14% |
1,612,094
-158,493
| -9% | -$6.25M |
|
15
Jazz Pharmaceuticals
JAZZ
$15.1B
| $49M | 2.13% |
335,159
+16,214
| +5% | +$2.4M |
|
16
argenx
ARGX
$54.1B
| $48.6M | 2.11% |
130,540
-17,977
| -12% | -$6.65M |
|
|
17
Xenon Pharmaceuticals
XENE
$6.55B
| $47.5M | 2.06% |
1,325,832
-1,034,582
| -44% | -$38.2M |
|
|
IGMS
18
DELISTED
IGM Biosciences
IGMS
| $45.8M | 1.99% |
3,334,355
| – | – |
|
|
OSH
19
DELISTED
Oak Street Health, Inc.
OSH
| $41.1M | 1.78% |
1,061,295
-359,322
| -25% | -$11.6M |
|
|
CTLT
20
DELISTED
CATALENT, INC.
CTLT
| $40.1M | 1.74% |
+610,304
| New | +$37.7M |
|
|
21
DexCom
DXCM
$28.6B
| $39M | 1.69% |
+336,048
| New | +$37.6M |
|
22
Stryker
SYK
$121B
| $39M | 1.69% |
136,464
+30,584
| +29% | +$8.11M |
|
23
Stoke Therapeutics
STOK
$1.86B
| $34.5M | 1.5% |
4,145,396
+3,502,966
| +545% | +$31.6M |
|
|
24
BioMarin Pharmaceuticals
BMRN
$11.3B
| $32.6M | 1.41% |
+335,170
| New | +$34.7M |
|
25
Sarepta Therapeutics
SRPT
$1.82B
| $31.9M | 1.39% |
+231,595
| New | +$30M |
|
Similar funds
ORI
GAI
HCMG
FMI
FCM
PP
AM
BFO